Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) Short Interest Down 51.1% in April

Intellipharmaceutics International Inc. (OTCMKTS:IPCIFGet Rating) (TSE:I) was the recipient of a large drop in short interest in April. As of April 15th, there was short interest totalling 2,300 shares, a drop of 51.1% from the March 31st total of 4,700 shares. Based on an average daily volume of 9,700 shares, the days-to-cover ratio is presently 0.2 days.

Intellipharmaceutics International stock opened at $0.12 on Friday. The stock has a market cap of $4.06 million, a PE ratio of -0.44 and a beta of 1.69. The stock has a 50-day moving average price of $0.13 and a 200 day moving average price of $0.13. Intellipharmaceutics International has a 52 week low of $0.08 and a 52 week high of $0.30.

Intellipharmaceutics International (OTCMKTS:IPCIFGet Rating) (TSE:I) last posted its quarterly earnings data on Monday, February 28th. The company reported ($0.17) EPS for the quarter.

About Intellipharmaceutics International (Get Rating)

Intellipharmaceutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.

Further Reading

Receive News & Ratings for Intellipharmaceutics International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International and related companies with MarketBeat.com's FREE daily email newsletter.